Samuel Zhang, PhD, is responsible for global strategy and business development as Innovent. Dr. Zhang has a PhD in Molecular Biology from Columbia University, an MBA from the Wharton School of the University of Pennsylvania, and a BS in Biology from Peking University. Dr. Zhang brings over 20 years of industry experience across the entire drug research, development and commercialization spectrum. He has a successful track record in identifying emerging industry trends and promising assets at an early stage, enabling major R&D decisions, and facilitating strategic transactions. Prior to joining Innovent, Dr. Zhang served as CBO at Gracell and NeoImmuneTech and led their global partnership discussions, including the $1.2B Gracell acquisition by AstraZeneca. He has also held positions of increasing responsibility at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.